Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234045 | 0.94 | ALDH1A1 (0.35) | ALDH1A1LMNAALOX5CHRNB2CHRNB4 | |
| SCHEMBL5110203 | 0.86 | — | — | |
| SCHEMBL24703880 | 0.86 | ALDH1A1 (0.42) | ALDH1A1LMNAALOX5CHRNB2CHRNB4 | |
| SCHEMBL22205611 | 0.86 | LMNA (0.44) | ALDH1A1LMNAALOX5CHRNB2CHRNB4 | |
| SCHEMBL29991123 | 0.84 | ALDH1A1 (0.41) | ALDH1A1LMNAKDM5A | |
| SCHEMBL4019745 | 0.81 | PHF8 (0.39) | ALDH1A1LMNAALOX5TSHRMEN1 | |
| SCHEMBL211903 | 0.80 | ALDH1A1 (0.60) | ALDH1A1LMNAKDM5A | |
| SCHEMBL6541852 | 0.80 | CAMK2A (0.39) | ALDH1A1LMNAALOX5CHRNB2CHRNB4 | |
| SCHEMBL20845950 | 0.78 | CYP1A2 (0.47) | ALDH1A1LMNAALOX5CHRNB2CHRNB4 | |
| SCHEMBL4000043 | 0.78 | ALDH1A1 (0.37) | ALDH1A1LMNAALOX5CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365067-B2 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20070197570-A1 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1746095-A1 | INDANOL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197570-A1 | Indanol derivative | BDKRB2, BDKRB1, TACR2 | ALDH1A1 1329/4885LMNA 4707/4885ALOX5 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.